QA-68

• Description :

  QA-68 (QA-68-ZU81) is an effective PROTAC-class BRD9 degrader. QA-68 can inhibit cell cycle progression and cell colony formation. QA-68 has antiproliferative activity against acute myeloid leukemia (AML) cell lines[1]. QA-68 can be formed by a target protein ligand (red part) EA-89 (HY-170314), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-I (HY-131318), and a PROTAC linker (black part) Ethyne-C2-Pip-CO-Pip-Boc (HY-170315) . E3 ubiquitin ligase and linker can form Lenalidomide-ethyne-C2-Pip-CO-Pip (HY-170319) .

• Product Name Alternative :

  QA-68-ZU81

• UNSPSC :

  12352005

• Target :

  Epigenetic Reader Domain; PROTACs

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; PROTAC

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/qa-68.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CCCN1C=C(C2=C(C1=O)C=C(C(NC3CCS(CC3)(=O)=O)=O)S2)C4=CC=C(C5=C4)N(C=C5C)CC6CCN(CC6)C(CCC(N7CCN(CC7)C(N8CCN(CC8)CCC#CC9=CC=CC%10=C9CN(C%10=O)C%11CCC(NC%11=O)=O)=O)=O)=O

• Molecular Formula :

  C61H72N10O10S2

• Molecular Weight :

  1169.42

• References & Citations :

  [1]Weisberg E, et al. BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma. Blood Cancer J. 2022 Jul 19;12 (7) :110.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  BRD9